We are an experienced and dynamic team, with extensive commercial experience in formulation science and drug delivery. We also have a strong background in patents and bringing products to the market.
Our management team combines 120 years’ experience in life science and our business model is built on strong financial and business administration skills.
Board of Directors
Howard Stevens – Chairman
Professor Howard Stevens is a registered pharmacist whose career spans four decades of management of industrial research and development in the UK and Europe in large multinationals and small drug delivery companies. He has been involved in the formation of several successful spin-out businesses and served as the Pfizer Professor of Drug Delivery at the University of Strathclyde from 1998-2009. He has an extensive scientific and patent publication record, is a fellow of the RPSGB, RSC and APSGB and served as Chairman of the APSGB in 2001.
Carol Thomson – Chief Operating Officer
Dr Carol Thomson has had a varied career in management in the science sector and developed strong operational management and leadership skills at Thomson Reuters, where she managed the Pharmaceutical Patents Business Unit of the World Patents Index. Following this, Carol spent three years at the University of Strathclyde in a Research Business Development role and subsequently as Research Policy Manager. Carol has a degree in Genetics and PhD from the University of Sheffield.
Alex Mullen – Chief Scientific Officer
Professor Alex Mullen is a registered pharmacist with commercial R&D experience, specialising in oral dosage formulation development. Professor Mullen has an extensive research portfolio, encompassing oral and vesicular drug delivery technologies, controlled release, drug eluting stents, liposomes and vaginal drug delivery. Professor Mullen provides scientific direction as Chief Scientist for drug delivery and formulation.
Fiona McInnes – Development Director
Dr Fiona McInnes is a registered pharmacist with over 10 years’ experience in formulation development and evaluation, both in vitro and in clinical proof of concept studies. She has particular expertise in the areas of nasal and oral modified release, having completed her PhD in nasal drug delivery. Having worked extensively in collaboration with the wider pharmaceutical industry, Fiona uses her experience to steer the scientific development of the company, liaising with clients and partners and leading the company’s research and development activities in the area of chronopharmaceutics.